VB-201

N/A

Report date: 2024/06/17 18:22:03
NME

Base Information

Drug NameVB-201
Drug Alias NameCI-201VB-201
ClassificationSmall molecules
Mechanisms of ActionToll like receptor 2 antagonistsMonocyte differentiation antigen CD14 inhibitors
TargetsToll like receptor 2Monocyte differentiation antigen CD14
Therapy Area/IndicationsPlaque psoriasisCoronavirus Disease 2019 (COVID-19)Inflammation +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaUnited StatesPoland +[7] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNotable Labs Ltd
China Registration ClassN/A

Develop Information

Active CompaniesVascular Biogenics Ltd. Operating As Vbl Therapeutics
Inactive CompaniesUtah State UniversityUniversity Of California, Los Angeles
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsPlaque psoriasisInflammationPsoriasis +[6] 

Other Information

ATC CodeN/A
Related LinksN/A